TOKYO, March 01, 2026 (GLOBE NEWSWIRE) — OrganTech, Inc. announced that its research team has defined a minimal stem cell set required for functional hair follicle regeneration in vitro, establishing a defined cellular framework that may inform next-generation regenerative strategies for alopecia and related indications.
Published in Biochemical and Biophysical Research Communications, the study further validates OrganTech’s organ-level regeneration platform built upon epithelial–mesenchymal interaction biology.
In vitro–regenerated murine hair follicles
A collaborative research team led by Koh-ei Toyoshima (General Manager of Research and Development, OrganTech., Inc.), Miho Ogawa (Director and Chief Technology Officer, OrganTech., Inc.), and Takashi Tsuji (former Team Leader, Organ Induction Research Team, RIKEN Center for Biosystems Dynamics Research) identified a previously uncharacterized accessory mesenchymal cell population—designated hair follicle regeneration–supporting cells—as an essential component for functional follicle regeneration under defined in vitro conditions.
In this study, the investigators established a controlled culture system for hair follicle reconstruction. Adult hair follicle–derived epithelial stem cells and dermal papilla cells were combined to reconstruct follicle organ germs. While these structures formed hair bulbs, they required an additional accessory mesenchymal population to achieve sustained downgrowth and hair shaft production.
By incorporating the newly identified supporting cell population, the team generated three–stem-cell–derived organ germs capable of regenerating fully functional hair follicles under defined in vitro conditions. The reconstructed follicles exhibited hair bulb formation, sustained downgrowth, and hair shaft production, demonstrating hair cycle–associated functionality.
Unlike current pharmacological treatments such as minoxidil or finasteride, which primarily slow hair loss progression, OrganTech’s approach is designed to reconstruct functional hair follicle units at the organ level through precisely defined cellular architecture.
Alopecia affects tens of millions of individuals worldwide and represents a significant and expanding commercial opportunity. The global hair restoration market is projected to exceed $15 billion within the coming decade, reflecting growing demand for durable, biologically based treatment solutions.
“This work defines a foundational cellular configuration for functional hair follicle regeneration,” said Yoshio Shimo, Representative Director and CEO of OrganTech. “Beyond hair biology, it reinforces our broader strategy of organ-level regenerative medicine, where precisely orchestrated epithelial and mesenchymal interactions enable stable and functional tissue reconstruction.”
The study advances understanding of hair follicle development, regeneration, and hair cycle regulation while providing a defined cellular blueprint for translational research. More broadly, it underscores a key principle in three-dimensional organ regeneration: sustained organ maturation may require accessory cell populations in addition to canonical epithelial–mesenchymal cell pairs.
OrganTech has filed international patent applications covering its organ germ–based regenerative technologies and is advancing a staged clinical translation strategy targeting alopecia and related regenerative indications.
Publication Information
Title
Fully Functional Hair Follicle Organ Regeneration Using Organ-Inductive Potential Stem Cells with an Accessory Mesenchymal Cell Population in an In Vitro Culture System
Authors
Koh-ei Toyoshima, Ayako Tsuchiya, Miho Ogawa, Miki Takase, Tarou Irié, Masayuki Yanagisawa, Richard H. Kaszynski, Hiroshi Fujimaki, Kyoko Baba, Takayuki Sugimoto, Akira Takeda, Akio Sato, and Takashi Tsuji
Journal
Biochemical and Biophysical Research Communications
DOI
10.1016/j.bbrc.2026.153459
About OrganTech, Inc.
OrganTech is a regenerative medicine company founded on the organ germ method, a technology platform originally developed through pioneering research in epithelial–mesenchymal interaction–driven organogenesis. The company is advancing next-generation bioengineered organ technologies, including hair follicle regeneration, dental bio-hybrid implants, and three-dimensional artificial skin systems. OrganTech aims to establish scalable organ-level regenerative solutions addressing large unmet medical needs worldwide.
Contact Information
OrganTech, Inc.
Email: [email protected]
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/8b1a7e0a-9427-4651-9f08-73a343c58e8a
